We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Benchmark Holdings Plc | LSE:BMK | London | Ordinary Share | GB00BGHPT808 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 43.25 | 43.00 | 43.50 | 43.50 | 43.50 | 43.50 | 40 | 16:35:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 169.74M | -23.15M | -0.0313 | -13.90 | 321.62M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/1/2015 08:41 | Ha glad I qualified it... | hydrus | |
27/1/2015 08:26 | Hmm not convinced it will fall that far but who knows. | hydrus | |
27/1/2015 08:22 | Looking to buy some back if it gets back to the placing price. Think price got a bit carried away after it was tipped. | phowdo | |
27/1/2015 08:16 | Seems like an overreaction, massive growth prospects here | hydrus | |
19/1/2015 15:24 | If you would like to hear Benchmark discuss their full year results we will be hosting a webinar with company management on the 28th of January at 2.30pm. They will give a 25 minute presentation with an opportunity for Q&A at the end. If you would like to participate, please register now: After registering, you will receive a confirmation email containing information about joining the webinar. If you would like to submit any questions for management ahead of the meeting please send them to hannah@equitydevelop Thanks, The Equity Development Team | hannahh | |
09/1/2015 09:11 | Next stop 140. | cestnous | |
08/1/2015 16:52 | Thanks Cest. Upped my stake by 50% (200) | petewy | |
08/1/2015 14:31 | Woodford goes from 10 to 14.5% :¬) | cestnous | |
07/1/2015 10:03 | 145 first stop cestnous | gucci | |
06/1/2015 13:31 | Invesco gone from 15.5 mil. to 29 mil. | cestnous | |
29/12/2014 20:17 | JakNife, The directors have not sold any shares at all during this fundraising. However, the process of issuing additional shares which have been bought by institutions enlarged the total number of shares in issue. Whilst the number of shares owned by directors remained static the percentage of the company they owned reduced, therefore their holding is said to be diluted. Price is irrelevant. Dibbs | dibbs | |
29/12/2014 16:37 | Haven't they only been diluted by recent placement? | phowdo | |
12/12/2014 12:12 | Hi, Our new note on Benchmark is available on our website: www.equitydevelopmen Registration is free. Thanks, The Equity Development team | hannahh | |
11/12/2014 12:48 | Equity Development note out: VALUATION "Extending our previous analysis (see notes, 10 September and 24 June) we believe that a discounted cash flow (DCF) analysis give a relatively clear view on potential cash flows from market expansion and product campaigns, fuelled by BMK's growing product development portfolio. Our DCF matrix, using a 10%-12% discount rate assumption and long-term FCF growth of 1.5%-3.0%, comfortably justifies the current market value. Depending on future positive news regarding product development (including HypoCat - not in current valuation) and other catalysts, we anticipate further value creation. Choosing an average from 10.0% - 14.0%, and adjusting for FY14e's net debt, suggests a market capitalisation of ~£312m. In terms of the new number of shares, this would equate to fair value per share of 142 pence." | aishah | |
10/12/2014 16:00 | Cheers Gucci; may we both make a mint :¬) | cestnous | |
09/12/2014 14:08 | nice lot of buying and l2 looking strong | gucci | |
09/12/2014 12:25 | wellcome Cestnous | gucci | |
09/12/2014 11:33 | Hi all, Just bought in. | cestnous | |
09/12/2014 09:31 | good chance for a topup at these levels - on support | gucci | |
08/12/2014 14:00 | this tends to shoot up quite fast hoping for the last highs again soon | gucci |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions